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1. Abstract 
Oral hypoglycemic drug therapy has successfully been used for controlling type-2 Diabetes 
Mellitus. Several new OHGs are flooding into the market and are prescribed to the patients 
depending upon effect and patient compliance, but no accurate combination of drugs has either 
been established or being customized that can exactly adapt to the biological system of patents. 
Since physical parameter differs from person-to-person, a comprehensive analysis is required to 
determine the right combination of OHGs. The current study aims towards a survey based 
analysis of OHG therapy in T2DM patients to observe the glycemic control through 
measurement of FBS, PPBS and HbA1c at specific time intervals. Briefly, 15 T2DM patients 
were observed longitudinally over 6 months for their glycemic control in response to different 
combination/mono OHG therapy. It was hypothesized that combination therapy of Biguanides 
(i.e Metformin) with other OHDs should give the best therapeutic benefits. For this subjects were 
selected within the Institutional community and the nearby locality. They were divided into three 
groups as per the OHG therapy (Group 1: Biguanide only; Group 2 Thiazolidinedion+Biguanide 
+Sulfonolyrea; and Group 3: Dipeptidyl Peptidas -4 inhibitor+Sulfonolyrea). With informed 
consent, they were instructed to respond to a prepared Questionnaire involving diabetic history 
along with medical concerns like any complication of vital organs and limbs. The glycemic 
control was evaluated from FBS, PPBS and HbA1c measurements. Survey was conducted in 2 
phases with a gap duration of 6 months. Data was obtained and statistical analysis was done. 
Subject variation was calculated by ANOVA. Paired –t test was carried out to derive the 
response difference at two time points (p ≤ 0.05) among three groups. Single factor ANOVA test 
was done. The results showed that Gr-I with Biguanides got significant therapeuric benefit over 
6 months as obtained from FBS (p = 0.009) and HbA1c (p = 0.01). It also conclude that in 
starting phase of OHGs, Biguanide monotherapy has the best therapeutic benefit over the 
combination therapies. 
Keywords:,T2DM, OHGs, Biguanide, Thiazolidinedion , ANOVA, Paired –t- test.  
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2. Introduction 
Diabetes (also called diabetes mellitus) is group of metabolic disease in which person 
experiences rise in blood Glucose. Reasons can be Insulin production is inadequate or because 
Body’s cell fails to respond properly to insulin or both. 
 Person experience  following change. 
 Polyuria (Frequent urination),Polydipsia (thirsty) and Polyphagia (hungry). 
 DM generally cannot be cured but it can be administered by controlling blood glucose. 
Poor management can lead to serious long-term body complications, and can increase the 
risk of cardiovascular disease. Usually good quality DM support and management 
increase the cost, complex, intensive-labor and time taking task. 
  
 Medicinal services benefit in 21st century have taken another measurement concentrating 
on out of Hospital Care, and a solid participatory segment from patients i.e  particularly 
in long-term and way of life related conditions, for example, DM. Individuals living with 
diabetes are confronted day by day with various difficulties in dealing with their 
condition. Treatment for T2DM administration includes meds as well as developing 
proof, which has recognized way of life alterations as the key element. 
 
2.1 There are three types of diabetes: 
Type 1 Diabetes 
 
T1DM also called Insulin-dependent where people take Insulin from outside the body other than 
insulin-dependent diabetes it is also called as early onset diabetes or juvenile diabetes. People 
usually develop Type 1 diabetes before reaching the age of 40, it has no age limit it can develop 
in early teenage or adulthood years. 
 Type 1 is very different from type 2 diabetes. 
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 Patients with type 1 diabetes take insulin injections for the rest of their life. They 
regularly check proper glucose levels by doing regularly blood tests and maintaining a 
proper Diet and Exercise. 
Type 2 Diabetes 
 
T2DM is a case where body does not produce enough insulin for proper functioning of metabolic 
activity or the body cells does not react to insulin i.e insulin resistance. 
 Some people may be able to control their T2DM symptoms by losing weight, doing 
regular exercise, maintaining a healthy diet and monitoring their blood glucose levels. 
However, T2DM is typically a progressive disease and it gradually gets worse. 
 Overweight and obese individuals have a much higher danger of creating T2DM 
contrasted with those with a solid body weight. Individuals with a considerable measure 
of instinctive fat, otherwise called focal weight, tummy fat, or stomach corpulence, are 
particularly at danger. Being overweight/fat causes the body to discharge chemicals that 
can destabilize the body's cardiovascular and metabolic frameworks. 
 Being overweight, physically inactive and eating the wrong foods all contribute to our 
risk of developing T2DM. According to a report published by researchers from Imperial 
College London in the journal Diabetologia “Drinking just one can of (non-diet) soda per 
day can raise our risk of developing type 2 diabetes by 22% “. 
 The risk of developing T2DM is also greater as we get older. Experts are not completely 
sure why, but say that as age increase we put on weight and become less physically 
active.  
 Researchers from the University of Edinburgh, Scotland, gave a report that low 
testosterone levels are linked to insulin resistance “Men whose testosterone levels are low 
have been found to have a higher risk of developing type 2 diabetes”.  
 
Gestational Diabetes 
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Gestational Diabetes affects females during pregnancy. Ladies having large amounts of glucose 
in their blood, and their body fails to create enough insulin to transport the greater part of the 
glucose into their cells, bringing about logically rising in level of blood glucose. In Gestational 
diabetes  the diagnosis is done during pregnancy. 
 The most of gestational diabetes patients controls their diabetes with regular exercise and 
healthy diet. Undiagnosed or uncontrolled gestational diabetes can raise the risk of 
complications during childbirth. 
 Scientists from the National Institutes of Health and Harvard University found that 
women whose diets before becoming pregnant were high in animal fat and cholesterol 
had a higher risk for gestational diabetes as compared to women had less amount of 
animal fat and cholesterol. 
Prediabetes  
 
Vast number of patients with T2DM at first had prediabetes. Their blood glucose levels are 
higher than ordinary, yet not sufficiently high to number a diabetes diagnosis. The cells in the 
body are getting to be impervious to insulin. 
2.2 Diabetes Is A Metabolism Disorder 
 Diabetes (diabetes mellitus) is under the category as a metabolism disorder.  
 The metabolism of diabetes is our body use digested food for getting energy and to obtain 
essential nutrients. Carbohydrate that we take is broken down into glucose, which is the 
main source of fuel for our body. Glucose is transported to various part of our body 
through bloodstream and glucose enters into the cytoplasm by the help of hormone called 
Insulin. 
 Under normal condition through the help of Insulin (produced by pancreas) glucose is 
broken down to produce energy. But A person with diabetes proper mechanism is halted 
either cell signaling molecules are mutated or passage of glucose molecule inside the cell 
is blocked or there is a large deposition of fat molecules over somatic cell that blocks 
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insulin-glucose molecules, resulting in deposition of glucose in extracellular matrix. This 
excess blood glucose eventually passes out of the body by urinal passage. So, even 
though the blood has plenty of glucose, the cells are getting less glucose producing less 
energy. 
 
Figure 1: Oral Hypoglycemic Drugs site of action. 
2.3 Therapautic in T2DM  
At present Six Class of Oral Hypoglycemic Drugs are available 
1. Biguanides(e.g Metformin). 
2. Sulfonylureas(e.g Glimepiride) 
3. Meglitinides(e.g Rapaglinide) 
4. Thiazolidinediones (e.g Pioglitazone) 
5. Dipeptidyl peptidas IV inhibitors (e.g Sitagliptin) 
6. α glucosidase inhibitors (e.g Acarbos) 
1. Biguanides 
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Biguanide an insulin sensitizer drug act against insulin resistance is considered to be effective in 
T2DM. Metformin is most preferred drug of biguanide because of its safety and effiency, it is 
also suggested for monotherapy or joint with other drugs. Joint guidelines from the AACE and 
ACE states that metformin can be initiated as initial line of monotherapy unless a contradiction 
such as renal disease, gastrointestinal intolerance ,hepatic disease or risk of lactic acidosis exists. 
Metformin is most widely used OHD in the world, but it can reach its peak value of effectiveness 
due to progressive β – cell failure. Metformin is only effective when sufficient insulin is present 
inside the cell as well as outside, because of this generally patients cannot maintain high tight 
glycemic control as disease progress.Due to safety and efficiency of Sulfonylureas and 
Metformin a commonly prescribed combination. 
2. Sulfonylureas  
SU are the most established and most broadly utilized drugs for the treatment of T2DM. In spite 
of the fact that SU treatment viably brings down blood glucose focuses by animating insulin 
emission from β-cells, treatment with Sulfonylureas is connected with a dynamic straight 
decrease in β-cell capacity. Possible powerlessness to keep up glycemic control mirrors a 
propelled phase of β-cell disappointment.  
Hypoglycemia is the most widely recognized and most genuine unfriendly occasion connected 
with SU treatment, primarily in view of insulin discharge being launched notwithstanding when 
glucose focuses are beneath the typical limit for ordinary physiologic glucose-fortified insulin 
discharge. Attributable to diminished viability of Sulfonylureas over the long haul and a related 
decrease in the insulin secretory store, blend treatment has concentrated basically on including 
insulin-sharpening meds, including metformin and thiazolidinedione. 
3. Meglitinides 
Meglitinides, for example, repaglinide and nateglinide are prandial insulin releasers that 
stimulate  fast insulin emission. Repaglinide (NovoNorm®, Prandin®, GlucoNorm®) is the first 
clinically accessible insulin secretagogues that particularly improves early-stage prandial insulin 
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reaction by expanding the affectability of β-cells to raised glucose levels, delivering a more 
noteworthy insulin discharge under hyperglycemic conditions. Repaglinide is taken orally 
instantly before a feast and has been demonstrated to especially lessen postprandial 
hyperglycemia.Lower danger of hypoglycemia makes these operators an appealing choice for 
some elderly patients. This could be identified with an in vitro finding that repaglinide expands 
insulin discharge from β-cells just in the vicinity of glucose. 
4. Thiazolidinediones 
The thiazolidinediones are insulin-sensitizing drugs that enhance entire body insulin affectability 
through gene regulation. These operators expand glucose uptake and diminish rates of 
gluconeogenesis in the liver. Diminishments in plasma insulin concentration and bringing down 
of circling triglycerides are extra backhanded components that may help enhance entire body 
insulin affectability. Thiazolidinediones have additionally been known to enhance β-cell work 
and decrease insulin resistance. 
5. Dipeptidyl peptidas IV inhibitors 
The dipeptidyl peptidase-4 (DPP-4) inhibitors are another class of oral medications for the 
treatment of T2DM. As the name proposes DPP-4 inhibitors repress the activity of DPP-4, the 
enzyme in charge of the peripheral degradation of GLP-1. There are as of now three medications 
accessible for clinical use in this class – sitagliptin, vildagliptin and saxagliptin. DPP-4  will be  
utilized either as monotherapy or as a part of blend with metformin, sulphonylureas or a mix of 
both. The rates of hypoglycaemia connected with these medications are 6–10 times lower than 
with sulphonylureas. They have likewise been indicated to be weight neutral.DPP-4 inhibitors 
are all around endured, with hypoglycaemia just happening when utilized as a part of mix with 
sulphonylurea treatment. The present medications are cleared by hepatic metabolism and renal 
discharge. Sitagliptin and vildagliptin are not authorized for utilization in renal debilitation, 
though saxagliptin can be utilized at a diminished measurements. There is a proposal from 
pooled information of expanded rates of contaminations, particularly nasopharyngitis and urinary 
13 |  P a g e
 
tract diseases, which recommends a part for DPP-4 action in typical safe reconnaissance, 
however whether this is clinically huge is still to be established. 
6. α glucose inhibitors  
A Drug may be characterized by the chemical type of the active ingredient or by the way it is 
utilized to treat a specific condition. Every drug can be characterized into one or more 
medication classes.  
Alpha-Glucosidase is one of the enzymes in charge of breaking down carbohydrates to smaller 
sugar particles like glucose, sothat carbohydrates can be re absorbed.  
Alpha-Glucosidase inhibitors work by focused and reversible inhibitors of these intestinal 
enzymes. They decrease the processing of sugars and postponement glucose retention. This 
outcomes in a smaller and slower ascent in blood glucose levels taking after suppers, and viably 
for the duration of the day. 
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3. Objective: 
 Comprehensive analysis will help to study the working of Oral 
Hypoglycemic drugs better. 
 With proper combination of different groups effect of drugs could be 
maximized. 
 Pinpointing which drug or combination of drugs gives the best result. 
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4. Literature Review 
  
Figure 2 & 3: Values for HbA1c and FBS & PPBS respectively.  
4.1 Drug effectiveness 
In a recent analysis ,Rao et al. have shown combination therapy with Metformin and 
Sulfonylureas significantly increased the relative risk of cardiovascular hospitalization or 
mortality. 
1. Blood glucose level reduced when T2DM were diagnosed with Pioglitazone , on 
the other hand triglyceride levels were decreased with increase in high-density 
lipoprotein cholesterol  levels were observed which  lead to  reduction in 
cardiovascular risk benefit could be boomeranged with elevation in weight gain. 
Combination therapy of Pioglitazone with metformin or a sulfonylurea were given to 
those patients whose condition were worst, and the blood glucose level were not 
controlled with mono-therapy. the results obtained  were very much favorable to 
combination therapy. There is a need for large-scale, long-term studies comparing the 
effectiveness of combination therapy that includes pioglitazone with that of other 
combinations of anti-diabetic drugs. A large-scale and long-term studies comparing 
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the effectiveness of combination therapy including pioglitazone with that to other 
combinations of OHDs. 
 
2. Metformin and Troglitazone have different mechanisms of action, despite of 
variation in mechanism  are equally effective in lowering blood glucose 
concentrations in patients with T2DM. Combination therapy of metformin and 
troglitazone therapy had improvement in  blood glucose control, without interfering 
of insulin secretion and with reversal of the two principal pathophysiologic 
abnormalities. 
 
Combination therapy of troglitazone and metformin resulted in no further decrease of 
endogenous glucose production. mono-therapy of troglitazone  had no significant 
effect on endogenous glucose. However, reason for lowering of endogenous glucose 
production when metformin was added to troglitazone  became a  difficult task to 
explain, particularly because these patients had a significant improvement in 
glycemic control during combined treatment. 
3. Sitagliptin indicated more prominent adequacy and preferable decency over a α-
glucosidase inhibitor when added to stable measurements of metformin or 
pioglitazone. These discoveries bolster the utilization of sitagliptin in Japanese 
patients with sort 2 diabetes deficiently controlled by insulin-sharpening specialists.  
 Both HbA1c and FPG diminished from standard with every treatment, with no 
measurably huge contrasts between medicines. An essentially lower frequency of 
reported hypoglycaemia was seen with sitagliptin contrasted and sulfonylurea (6.2% 
versus 27.8%; p < 0.001). Body weight diminished altogether with sitagliptin yet not with 
sulfonylurea. Fundamentally a larger number of patients on sitagliptin than on 
sulfonylureas attained to a composite end-purpose of >0.5% HbA1c decrease with no 
reported hypoglycaemia or increment in body weight (44.1% versus 16.0%; p < 0.001).  
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 In this investigation of elderly patients with T2DM, contrasted and sulfonylurea, 
sitagliptin gave comparable glycaemic adequacy less hypoglycaemia and with body 
weight reduction.  
 
4. The blend of metformin and a sulfonylurea is generally utilized as a part of sort 2 
diabetes mellitus. Numerous patients on this mix treatment don't accomplish or keep 
up glycemic targets and require the expansion of a third antihyperglycemic 
specialists.  
 
5. The unfavorable impacts of metformin primarily comprise of measurements ward 
gastrointestinal issue and uncommon cases or life-debilitating lactic aciaosis. Kidney 
disappointment decreases metformin end. Metformin once in a while causes 
hypoglycaemia and has no impact on body weight. It doesn't build tumor related 
mortality. It at times reasons vitamin B12 lack prompting macrocytic weakness or 
fringe neuropathy. Metformin chiefly conveys a danger of cooperations with 
medications that disable renal capacity, for example, non-steroidal calming 
medications and iodinated differentiation media. Renal disappointment can prompt 
metformin gathering and an expanded danger of lactic acidosis.  
 
6. Vildagliptin was the most utilized medication among DPP-4 inhibitors. 
Conclusions.Sulfonylureas were the most utilized medication for diabetes treatment. 
Patients treated with DPP-4 inhibitors had higher adherence and control of diabetes, 
with lower rates of hypoglycemia and CVE, bringing about lower social insurance 
costs. 
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5. Methodology 
5.1 WORK FLOW DIAGRAM 
 
 
 
 
 
Step 1 
• Collection of data. 
Step 2 
• Blood Glucose measurement. 
Step 3 
• Analysis of statistical data. 
Prepared Questionnaire Collection of Data for Time 
period 1 
Total 15 subjects were taken 
for study. 
Collection of Data for Time 
period 2 (same Subjects) 
Difference between two time 
period is 6 months. 
Division of groups 
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Statistical Data Analysis 
Single Factor ANOVA Paired t test 
Results 
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5.2 Subject selection 
Professors, currently employed in an institute, community or public health setting, Government 
employers ,private businessman, workers working in any site, security Guards, were recruited to 
participate. All of them were recruited through convenience sampling in cooperation with several 
proper agreement in relation to consent form that was prepared. 
 
Procedures 
 
Study was done by visiting each professors office and data was collected. Apart from that to 
maximize the number of participation ; information form friend circle was also taken. Study 
advertisements provided a brief overview of the purpose of the survey and directed participants 
to an online survey created using Survey Monkey and Google Forms. Instructions for completing 
the surveys and relevant information regarding of the purpose of the research and confidentiality 
procedures were included within the online survey itself. 
Data collection was done between November 2014 to May 2015. Exactly six months gap was 
maintained between 2 successive survey to the same person so as to do comparison. 
5.3 Estimation of FBS, PPBS and HbA1c. 
 
FBS should be taken before intake of food. And PPBS should be taken after 2 hours of uptake of 
food . these 2 measurement were taken by the help of instrument called “Glucometer”. 
With correctly calibrated. To measure HbA1c level subject were asked to provide the data of 
recently obtained HbA1c level. 
Data collected was divided among groups as follows:- 
FBS data collected was divided into 3 groups according to intake of medicine. 
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1. G1 Biguanide  
2. G2 (Thiazolidinedion + Biguanide + Sulfonolyrea)  
3. G3 (DPP-4+ Biguanide + Sulfonolyrea) 
There are 2 test date  
Difference between 2 test date  i.e Test Date 1 and Test date 2 is 6 months. Deviation from 126 
was also measured, greater than 126 mg/dl seperate subjects form normal.some values comes out 
to be positive some are negative. 
 
Figure 4: Group 1,2 and 3. Divided on the basis of FBS level. 
Similarly for PPBS and HbA1c data collected was divided into 3 groups according to intake of 
medicine. 
1. G1 Biguanide  
2. G2 (Thiazolidinedion + Biguanide + Sulfonolyrea)  
3. G3 (DPP-4+ Biguanide + Sulfonolyrea) 
There are 2 test date  
Difference between 2 test date  i.e Test Date 1 and Test date 2 is 6 months. Deviation from 200 
mg/dl for PPBS and 7.0 for HbA1c  was also measured.  
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Figure 5: Group 1,2 and 3. Divided on the basis of PPBS level. 
 
 
Figure 6: Group 1,2 and 3. Divided on the basis of HbA1c level. 
5.4 Statistical Data Analysis. 
1. Single factor ANOVA. 
2. Paired –t- test. 
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ANOVA was used to compare the mean of two or more groups. Subject were taking only 
medication so one factor was taken into consideration.  
Null Hypothesis: Single factor ANOVA was done so as to ensure the Subject Variation in the 
group should be insignificant. 
Paired –t- test was done to compare the mean of two groups. p value determines the effectiveness 
of any drug therapy. p value determined through MS Excel.  
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6. Result and Discussion 
6.1 ANOVA test result 
1. ANOVA test result for Group 1 FBS p-value =0.532. ANOVA  test to be considered 
variation between the group should be p<0.01 but here higher value states that Single 
factor ANOVA was very insignificant. 
 
Figure:7 Result of ANOVA : single factor for FBS Group 1. 
 
2. ANOVA test result for Group 2 FBS p-value =0.353. ANOVA  test to be considered 
variation between the group should be p<0.01 but here higher value states that Single 
factor ANOVA was very insignificant. 
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Figure:8 Result of ANOVA : single factor for FBS Group 2. 
 
3. ANOVA test result for Group 3 FBS p-value =0.509. ANOVA  test to be considered 
variation between the group should be p<0.01 but here higher value states that Single 
factor ANOVA was very insignificant. 
 
Figure:9 Result of ANOVA : single factor for FBS Group 3. 
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4. ANOVA test result for Group 1 PPBS p-value =0.701. ANOVA  test to be considered 
variation between the group should be p<0.01 but here higher value states that Single 
factor ANOVA was very insignificant. 
 
Figure:10 Result of ANOVA : single factor for PPBS GROUP 1. 
5. ANOVA test result for Group 2 PPBS p-value =0.455. ANOVA  test to be considered 
variation between the group should be p<0.01 but here higher value states that Single 
factor ANOVA was very insignificant. 
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Figure:11 Result of ANOVA : single factor for PPBS GROUP 2. 
6. ANOVA test result for Group 3 PPBS p-value =0.546. ANOVA  test to be considered 
variation between the group should be p<0.01 but here higher value states that Single 
factor ANOVA was very insignificant. 
 
Figure:12 Result of ANOVA : single factor for PPBS GROUP 3. 
7. ANOVA test result for Group 1 HbA1c   p-value =0.681. ANOVA  test to be considered 
variation between the group should be p<0.01 but here higher value states that Single 
factor ANOVA was very insignificant. 
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Figure:13 Result of ANOVA : single factor for HbA1C GROUP 1. 
8. ANOVA test result for Group 2 HbA1c   p-value =0.601. ANOVA  test to be considered 
variation between the group should be p<0.01 but here higher value states that Single 
factor ANOVA was very insignificant. 
 
Figure:14 Result of ANOVA : single factor for HbA1C GROUP 2. 
 
9. ANOVA test result for Group 3 HbA1c   p-value =0.570. ANOVA  test to be considered 
variation between the group should be p<0.01 but here higher value states that Single 
factor ANOVA was very insignificant. 
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Figure:15 Result of ANOVA : single factor for HbA1C GROUP 3. 
From the above calculation it was interpreted that p value in all the case were >0.01 so Subject 
variation is insignificant. 
6.2 Paired –t- test result 
 To ensure the result to be accurate p value <0.01. 
 High p value signifies the acceptance of hypothesis that was taken. 
 If the P value is large, the data do not give you any reason to conclude that the overall 
means differ. Even if the true means were equal.it don't have convincing evidence that 
they differ. 
1. GROUP 1 PAIRED –t- TEST.  
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Figure: 16 Result of Paired t test for FBS. 
 
Figure: 17 Result of Paired t test for PPBS. 
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Figure: 18 Result of Paired t test for HbA1c. 
 From Group 1 paired –t- test its been noticed that for FBS and HbA1c value of 
P(T<=t) was very significant. And for PPBS P value came to be very high so it’s not 
significant. 
2. GROUP 2 PAIRED –t- TEST. 
 
Figure: 19 Result of Paired t test for FBS. 
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Figure: 20 Result of Paired t test for PPBS. 
 
Figure: 21 Result of Paired t test for HbA1c. 
 From Group 2 paired –t- test its been noticed that for FBS ,PPBS, HbA1c value of 
P(T<=t) was very in significant. 
3. GROUP 3 PAIRED –t- TEST 
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Figure: 22 Result of Paired t test for FBS. 
 
Figure: 23 Result of Paired t test for PPBS.. 
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Figure: 24 Result of Paired t test for HbA1c. 
 From Group 3 paired –t- test its been noticed that for FBS ,PPBS, HbA1c value of 
P(T<=t) was very in significant. 
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7. Conclusion 
 
HbA1c indicates intrinsic control that mean how glycated hemoglobin disappears ; which was 
found be significant in Group 1> Group 2 > Group 3. 
However FBS was not significant in Group 2 and Group 3 but found to be in Group 1. 
Biguanide(Metformin) is usually the 1
st
 line of drug in all the group it’s been there since it was 
prescribed for long. Other groups were added subsequently. Since the time gap is 6 months. We 
may get the significant difference in Group 2 and Group 3, if prolonged longitudinal study is 
conducted. 
Before 6 months at the point of 1
st
 test call all the patients were getting Biguanide ,from that 
point the Group 1 were not taken any additional medication. Group2 was added with 
Thiazolidinedion and Group 3 was added with Sulfonylurea and DPP-4. 
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